Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-73763989 and PD-1 inhibitor in chronic hepatitis B
NCT05275023Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of tomligisiran in Chronic Hepatitis B (CHB) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants Who Achieved Hepatitis B Surface Antigen (HBsAg) Seroclearance at 24 weeks. Started Jun 2022; status: completed.
02
Drugs
tomligisiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05275023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275023.